ROSGQ (Rosetta Genomics) EBIT per Share: $-7.57 (TTM As of Jun. 2017)


What is Rosetta Genomics EBIT per Share?

Rosetta Genomics ROSGQ -99.00% EBIT per Share is $-7.57 as of Jun. 2017.

Rosetta Genomics's EBIT per Share for the six months ended in Jun. 2017 was $-2.04. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2017 was $-7.57.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Rosetta Genomics's EBIT per Share or its related term are showing as below:

ROSGQ's 3-Year EBIT Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 12.75
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Rosetta Genomics's EBIT for the six months ended in Jun. 2017 was $-4.53 Mil.

Rosetta Genomics  (OTCPK:ROSGQ) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Rosetta Genomics EBIT per Share Related Terms

Rosetta Genomics EBIT per Share Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics EBIT per Share Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.28 -16.46 -15.45 -13.73 -9.31

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.01 -6.53 -3.80 -5.54 -2.04

Rosetta Genomics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Rosetta Genomics's EBIT per Share for the fiscal year that ended in Dec. 2016 is calculated as

EBIT per Share(A: Dec. 2016 )
=EBIT/Shares Outstanding (Diluted Average)
=-16.224/1.743
=-9.31

Rosetta Genomics's EBIT per Share for the quarter that ended in Jun. 2017 is calculated as

EBIT per Share(Q: Jun. 2017 )
=EBIT/Shares Outstanding (Diluted Average)
=-4.528/2.225
=-2.04

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2017 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-7.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-7.57 mean?
Rosetta Genomics (ROSGQ) has a EBIT per Share of $-7.57 as of Jun. 2017. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' EBIT per Share too high?
Rosetta Genomics' current EBIT per Share is $-7.57.
How does Rosetta Genomics' EBIT per Share compare to TEAR and IDTA?
Rosetta Genomics' EBIT per Share of $-7.57 can be compared against companies in the Medical Diagnostics & Research industry. The industry median EBIT per Share is 12.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.75, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Rosetta Genomics and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rosetta Genomics's current EBIT per Share is $-7.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current EBIT per Share of $-7.57. The current EBIT per Share is $-7.57. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current EBIT per Share is $-7.57 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.